Earlier studies have shown that a point mutation in methylenetetrahydrofolate reductase (MTHFR) gene is more prevalent in MA patients.29 This mutation (MTHFR C677T) results a 50% reduction in MTHFR activity, which can induce serum hyperhomocysteinemia.30 It has been shown that reduced level of homocysteine can diminish headache severity, attacks frequency and migraine disability, too.19 Therefore, pyridoxine supplementation may improve MA symptoms, through reduction of serum homocysteine concentration. The gene discussed is MTHFR; the disease is hyperhomocysteinemia.